ASH 2021 Focus on CAR-T

Advertisement
DocWire News EditorsASH Annual Meeting and Exposition 2021 | April 3, 2023
The chimeric antigen receptor (CAR) T-cell therapy lisocabtagene maraleucel (liso-cel) significantly improved event-free ...
Read More
DocWire News EditorsASH Annual Meeting and Exposition 2021 | April 6, 2023
According to results from the phase III BELINDA trial, patients with relapsed/refractory aggressive B-cell non-Hodgkin ...
DocWire News EditorsASH Annual Meeting and Exposition 2021 | April 6, 2023
The chimeric antigen receptor (CAR) T-cell therapy axicabtagene ciloleucel (axi-cel) demonstrated significant and ...
DocWire News EditorsASH Annual Meeting and Exposition 2021 | April 3, 2023
First-line treatment with the autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy axicabtagene ...
DocWire News EditorsASH Annual Meeting and Exposition 2021 | April 6, 2023
In a single-arm phase I/II study, infusion with CT103A, a novel fully human B-cell maturation antigen (BCMA)-targeted ...
DocWire News EditorsASH Annual Meeting and Exposition 2021 | April 6, 2023
Chimeric antigen receptor (CAR) T-cell therapy is a potentially life-saving option for patients with hematologic ...
DocWire News EditorsASH Annual Meeting and Exposition 2021 | April 6, 2023
According to results from the phase III BELINDA trial, patients with relapsed/refractory aggressive B-cell non-Hodgkin ...
DocWire News EditorsASH Annual Meeting and Exposition 2021 | April 3, 2023
Black Americans were severely under-represented in clinical trials that supported FDA approvals of chimeric antigen ...
DocWire News EditorsASH Annual Meeting and Exposition 2021 | August 31, 2023
Findings from phase II of the phase I/II MajesTEC-1 study on teclistamab were presented for the first time at the 2021 ...
DocWire News EditorsASH Annual Meeting and Exposition 2021 | August 31, 2023
A study reported updated results from the CARTITUDE-1 trial, which previously showed that cilacabtagene autoleucel ...
DocWire News EditorsASH Annual Meeting and Exposition 2021 | April 3, 2023
Prescribing chemotherapy is not a universal practice of advanced practice providers (APPs) in the oncology community, ...
DocWire News EditorsASH Annual Meeting and Exposition 2021 | April 3, 2023
According to new research presented during the 2021 ASH Annual Meeting, circulating tumor DNA (ctDNA) accurately ...
DocWire News EditorsASH Annual Meeting and Exposition 2021 | April 3, 2023
Chimeric antigen receptor (CAR) T-cell therapy with lisocabtagene maraleucel (liso-cel) significantly improved ...
DocWire News EditorsASH Annual Meeting and Exposition 2021 | August 31, 2023
Peripheral blood cytopenia is a persistent clinical challenge and, according to findings from the REGARDS trial, it may ...
DocWire News EditorsASH Annual Meeting and Exposition 2021 | April 19, 2023
Despite advances in novel therapies, survival rates remain poor for patients with relapsed/refractory aggressive B-cell ...
Rebecca AraujoASH Annual Meeting and Exposition 2021 | April 19, 2023
In a phase I trial, the B-cell maturation antigen (BCMA)–targeting chimeric antigen receptor (CAR) T-cell therapy ...
DocWire News EditorsASH Annual Meeting and Exposition 2021 | April 19, 2023
According to data from the ZUMA-7 trial, the chimeric antigen receptor (CAR) T-cell therapy axicabtagene ciloleucel ...
DocWire News EditorsASH Annual Meeting and Exposition 2021 | May 2, 2023
A recent study of KTE-X19 (also known as brexucabtagene autoleucel) supports the use of chimeric antigen receptor (CAR) ...
Advertisement
Advertisement
Advertisement
Latest News

March 18, 2025